Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.35 |
| ▸ | KDM6B | O15054 | 1/20 | 0.35 |
| ▸ | KDM5C | P41229 | 1/20 | 0.35 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.35 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | FLT1 | P17948 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11565232 | 0.88 | NAALAD2 (0.45) | NAALAD2ALDH1A1KMT2AMEN1CYP1A2 | |
| SCHEMBL16472473 | 0.82 | ALDH1A1 (0.39) | ALDH1A1LMNASLC15A2 | |
| SCHEMBL13955086 | 0.82 | NAALAD2 (0.33) | NAALAD2ALDH1A1KMT2AMEN1CYP1A2 | |
| SCHEMBL21012621 | 0.78 | TSHR (0.48) | ALDH1A1KMT2AMEN1LMNATSHR | |
| SCHEMBL19456828 | 0.78 | TDP1 (0.36) | ALDH1A1TDP1 | |
| SCHEMBL23894022 | 0.77 | — | — | |
| SCHEMBL20425149 | 0.76 | HMGCR (0.46) | ALDH1A1TSHRFFAR3HIF1ATDP1 | |
| SCHEMBL23777424 | 0.75 | TSHR (0.39) | NAALAD2ALDH1A1KMT2AMEN1CYP1A2 | |
| SCHEMBL26744419 | 0.74 | NAALAD2 (0.42) | NAALAD2ALDH1A1KMT2AMEN1CYP1A2 | |
| SCHEMBL22987344 | 0.74 | FAAH (0.41) | ALDH1A1KMT2ALMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 254 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651162-B1 | IMPROVED CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | IMMUNOGEN INC (US) | 2015-10-21 | — | — | EP | claimed |
| CN-101186613-B | Cytotoxic agents comprising new maytansinoids | IMMUNOGEN INC | 2014-09-17 | — | — | CN | claimed |
| US-7473796-B2 | Maytansinoid intermediates: N-alkyl- or aryldithioalkanoylalanines and N-alkanoyl- or aroylthioalkanoylalanines, e.g., N-methyl-N-(4-methyl-4-methyldithio-1-oxopentyl)-alanine; optical isomers and racemic mixtures; preparations from isobutylene sulfide and acetonitrile, methyl methanethiosulfonate, etc. | IMMUNOGEN INC. (US) | 2009-01-06 | — | — | US | claimed |
| US-20070270585-A1 | Maytansinoid intermediates: N-alkyl- or aryldithioalkanoylalanines and N-alkanoyl- or aroylthioalkanoylalanines, e.g., N-methyl-N-(4-methyl-4-methyldithio-1-oxopentyl)-alanine; optical isomers and racemic mixtures; preparations from isobutylene sulfide and acetonitrile, methyl methanethiosulfonate, etc. | IMMUNOGEN, INC. (US) | 2007-11-22 | — | — | US | claimed |
| CN-121021353-A | Purification method of 4-methyl-4- (methyldisulfanyl) pentanoic acid | 哈尔滨珍宝制药有限公司 | 2025-11-28 | — | — | CN | disclosed |
| CN-121021353-A | Purification method of 4-methyl-4- (methyldisulfanyl) pentanoic acid | 哈尔滨珍宝制药有限公司 | 2025-11-28 | — | — | CN | disclosed |
| US-20250114441-A1 | POLYMERIC VACCINE FOR OPIOID ADDICTION | THE JOHNS HOPKINS UNVERSITY | 2025-04-10 | — | — | US | disclosed |
| EP-4335851-A2 | PHARMACEUTICAL FORMULATIONS AND METHODS OF USE THEREOF | ImmunoGen, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| US-11897961-B2 | Anti-CD123 antibodies and conjugates and derivatives thereof | IMMUNOGEN, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| EP-4286387-A2 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | ImmunoGen, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| US-11834406-B2 | Conjugates of cell binding molecules with cytotoxic agents | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-12-05 | — | — | US | disclosed |
| EP-3380525-B1 | PHARMACEUTICAL FORMULATIONS AND METHODS OF USE THEREOF | IMMUNOGEN INC (US) | 2023-11-08 | — | — | EP | disclosed |
| CN-1956722-A | Improved cytotoxic agents containing novel maytansinoids | IMMUNOGEN INC (US) | 2007-05-02 | — | — | CN | disclosed |
| US-20070037972-A1 | For making maytansinoids with chiral amino acid side chains; maytansinoids may be conjugated to cell-binding agents such as antibodies and are useful therapeutics, especially for treatment of cancer; high yielding methods that avoid or reduce epimerization in coupling of side chain linker | MILLENNIUM PHARMACEUTICALS, INC. | 2007-02-15 | — | — | US | disclosed |
| WO-2006078809-A2 | METHOD FOR THE PREPARATION OF MAYTANSINOID ESTERS | IMMUNOGEN, INC. (US) | 2006-07-27 | — | — | WO | disclosed |
| US-20060167245-A1 | Method for the preparation of maytansinoid esters | IMMUNOGEN, INC. | 2006-07-27 | — | — | US | disclosed |
| WO-2006061259-A2 | CYTOTOXIC AGENTS COMPRISING NEW C-2 MODIFIED TAXANES | AVENTIS PHARMA S.A. (FR) | 2006-06-15 | — | — | WO | disclosed |
| EP-1651162-A2 | IMPROVED CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | Immunogen, Inc. (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2004103272-A2 | IMPROVED CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | IMMUNOGEN, INC. (US) | 2004-12-02 | — | — | WO | disclosed |
| US-20040235840-A1 | For therapy of tumors | IMMUNOGEN, INC. | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270585-A1 | Maytansinoid intermediates: N-alkyl- or aryldithioalkanoylalanines and N-alkanoyl- or aroylthioalkanoylalanines, e.g., N-methyl-N-(4-methyl-4-methyldithio-1-oxopentyl)-alanine; optical isomers and racemic mixtures; preparations from isobutylene sulfide and acetonitrile, methyl methanethiosulfonate, etc. | AASDHPPT, AADAT, SLC6A15 | NAALAD2 617/4885ALDH1A1 492/4885KMT2A 3969/4885 |
| US-20060167245-A1 | Method for the preparation of maytansinoid esters | PTMS, CYP4A11, CYP11B1 | NAALAD2 1081/4885ALDH1A1 638/4885KMT2A 4564/4885 |
| US-11897961-B2 | Anti-CD123 antibodies and conjugates and derivatives thereof | IL23R, CD22, IL2RA | NAALAD2 729/4885ALDH1A1 1167/4885KMT2A 3968/4885 |
| US-20040235840-A1 | For therapy of tumors | HCCS, SPR, PAICS | NAALAD2 1996/4885ALDH1A1 1022/4885KMT2A 3924/4885 |
| US-20070037972-A1 | For making maytansinoids with chiral amino acid side chains; maytansinoids may be conjugated to cell-binding agents such as antibodies and are useful therapeutics, especially for treatment of cancer; high yielding methods that avoid or reduce epimerization in coupling of side chain linker | MRTO4, SLC43A1, SLC7A1 | NAALAD2 1499/4885ALDH1A1 2721/4885KMT2A 1344/4885 |
| US-20250114441-A1 | POLYMERIC VACCINE FOR OPIOID ADDICTION | OPRM1, OPRK1, OPRL1 | NAALAD2 3733/4885ALDH1A1 2483/4885KMT2A 2167/4885 |
| US-11834406-B2 | Conjugates of cell binding molecules with cytotoxic agents | CD4, CD2, CD47 | NAALAD2 1457/4885ALDH1A1 3232/4885KMT2A 2878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.